{'52WeekChange': -0.49172848,
 'SandP52WeekChange': None,
 'address1': '1111 Dr. Frederik-Philips Boulevard',
 'address2': 'Suite 420',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 8.32,
 'askSize': 1300,
 'averageDailyVolume10Day': 34959612,
 'averageVolume': 5883260,
 'averageVolume10days': 34959612,
 'beta': None,
 'beta3Year': None,
 'bid': 8.29,
 'bidSize': 1100,
 'bookValue': 4.057,
 'category': None,
 'circulatingSupply': None,
 'city': 'Montreal',
 'companyOfficers': [],
 'country': 'Canada',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 11.404,
 'dayLow': 7.587,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.607,
 'enterpriseToRevenue': None,
 'enterpriseValue': 102309136,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 4.155857,
 'fiftyTwoWeekHigh': 24.01,
 'fiftyTwoWeekLow': 1.69,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 8210156,
 'forwardEps': -2.21,
 'forwardPE': -3.746606,
 'fromCurrency': None,
 'fullTimeEmployees': 30,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.06963,
 'heldPercentInstitutions': 0.72432,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/milestonepharma.com',
 'longBusinessSummary': 'Milestone Pharmaceuticals Inc., a biopharmaceutical '
                        'company, develops and commercializes etripamil for '
                        'the treatment of cardiovascular indications. It is '
                        'developing etripamil, a novel channel blocker, which '
                        'is in Phase III clinical trial for the treatment of '
                        'paroxysmal supraventricular tachycardia in the United '
                        'States and Canada, as well as for the treatment of '
                        'atrial fibrillation, angina, and other cardiovascular '
                        'indications. The company was founded in 2003 and is '
                        'headquartered in Montr√©al, Canada.',
 'longName': 'Milestone Pharmaceuticals Inc.',
 'market': 'us_market',
 'marketCap': 203896656,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_36171059',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -61120000,
 'nextFiscalYearEnd': 1640908800,
 'open': 9,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '514 336 0444',
 'previousClose': 8.91,
 'priceHint': 2,
 'priceToBook': 2.0409167,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 11.404,
 'regularMarketDayLow': 7.587,
 'regularMarketOpen': 9,
 'regularMarketPreviousClose': 8.91,
 'regularMarketPrice': 9,
 'regularMarketVolume': 53343745,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 24625200,
 'sharesPercentSharesOut': 0.0537,
 'sharesShort': 1322903,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 471941,
 'shortName': 'Milestone Pharmaceuticals Inc.',
 'shortPercentOfFloat': 0.0848,
 'shortRatio': 0.84,
 'startDate': None,
 'state': 'QC',
 'strikePrice': None,
 'symbol': 'MIST',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.807,
 'twoHundredDayAverage': 9.330956,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'fef8fa0a-f2b8-346f-8ec3-172c3e402265',
 'volume': 53343745,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.milestonepharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': 'H4M 2X6'}